{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:48:19Z","timestamp":1783468099995,"version":"3.55.0"},"reference-count":35,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["not applicable"],"award-info":[{"award-number":["not applicable"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Patients with psoriatic arthritis (PsA) experience impaired health-related quality of life (HRQoL). Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA, which has been associated with improvements in dermatologic endpoints in patients with PsA. To assess the extent to which tofacitinib affects patient HRQoL via improvements in dermatologic symptoms, including itch, data were pooled from patients with PsA who received tofacitinib in phase III studies (NCT01866668 and NCT01882439). Mediation modeling assessed the indirect effects (via Itch Severity Item [ISI] and Physician\u2019s Global Assessment of Psoriasis [PGA-PsO]) and direct effects (via all other factors) of tofacitinib treatment on dermatology-specific HRQoL (measured by Dermatology Life Quality Index [DLQI]). In the initial model, the treatment effect on DLQI was largely mediated by itch (ISI; p &lt; 0.0001) and PGA-PsO (p &lt; 0.01). The model was re-specified to assess the indirect effects only of itch and PGA-PsO on DLQI. Here, 17.7% of the treatment effect on DLQI was attributable to PGA-PsO (p = 0.0006), and 82.3% to itch (p &lt; 0.0001). Tofacitinib-dependent improvements in DLQI were primarily mediated by itch relief, in addition to improvements in PGA-PsO.<\/jats:p>","DOI":"10.3390\/jcm10184081","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T12:20:37Z","timestamp":1631190037000},"page":"4081","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Itch as Major Mediator of Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7766-6167","authenticated-orcid":false,"given":"Peter C.","family":"Taylor","sequence":"first","affiliation":[{"name":"Rheumatology and Musculoskeletal Sciences, Nuffield Department of Orthopaedics, University of Oxford, Oxford OX3 7LD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Bushmakin","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, CT 06340, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph C.","family":"Cappelleri","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, CT 06340, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Young","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, PA 19426, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Germino","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, NY 10017, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Yosipovitch","sequence":"additional","affiliation":[{"name":"Miller School of Medicine, University of Miami, Miami, FL 33146, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_3","first-page":"ii14","article-title":"Psoriatic arthritis: Epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jaad.2013.12.018","article-title":"Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey","volume":"70","author":"Lebwohl","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/acr.22831","article-title":"Global prevalence of spondyloarthritis: A systematic review and meta-regression analysis","volume":"68","author":"Stolwijk","year":"2016","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jaad.2015.05.001","article-title":"Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis","volume":"73","author":"Villani","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jaad.2005.10.008","article-title":"Quality-of-life issues in psoriasis and psoriatic arthritis: Outcome measures and therapies from a dermatological perspective","volume":"54","author":"Mease","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","first-page":"511","article-title":"Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis","volume":"24","author":"Husted","year":"1997","journal-title":"J. Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40744-018-0135-1","article-title":"Patient perspective on the burden of skin and joint symptoms of psoriatic arthritis: Results of a multi-national patient survey","volume":"6","author":"Merola","year":"2019","journal-title":"Rheumatol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40744-018-0120-8","article-title":"Skin involvement in psoriatic arthritis worsens overall disease activity, patient-reported outcomes, and increases healthcare resource utilization: An observational, cross-sectional study","volume":"5","author":"Merola","year":"2018","journal-title":"Rheumatol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1002\/acr.22044","article-title":"Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: Findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial","volume":"65","author":"Kavanaugh","year":"2013","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/annrheumdis-2014-205207","article-title":"A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: Elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative","volume":"73","author":"Gossec","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"key":"ref_14","first-page":"e27638","article-title":"IL-4, JAK-STAT signaling, and pain","volume":"2","year":"2013","journal-title":"JAKSTAT"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/nn.3289","article-title":"A subpopulation of nociceptors specifically linked to itch","volume":"16","author":"Han","year":"2013","journal-title":"Nat. Neurosci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e000808","DOI":"10.1136\/rmdopen-2018-000808","article-title":"Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e000806","DOI":"10.1136\/rmdopen-2018-000806","article-title":"Tofacitinib or adalimumab versus placebo: Patient-reported outcomes from OPAL Broaden\u2014A phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1111\/jdv.16433","article-title":"Tofacitinib in psoriatic arthritis patients: Skin signs and symptoms and health-related quality of life from two randomized phase 3 studies","volume":"34","author":"Merola","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014A simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin. Exp. Dermatol"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Cappelleri, J.C., Zou, K.H., Bushmakin, A.G., Alvir, J.M.J., Alemayehu, D., and Symonds, T. (2014). Patient-Reported Outcomes: Measurement, Implementation and Interpretation, CRC Press.","DOI":"10.1201\/b16139"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/09546634.2013.861891","article-title":"The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib","volume":"26","author":"Bushmakin","year":"2015","journal-title":"J. Dermatol. Treat."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/ecco-jcc\/jjw107","article-title":"Direct and indirect effects of tofacitinib on treatment satisfaction in patients with ulcerative colitis","volume":"10","author":"Su","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","article-title":"Translating the science of quality of life into practice: What do dermatology life quality index scores mean?","volume":"125","author":"Hongbo","year":"2005","journal-title":"J. Invest. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"340","DOI":"10.2340\/00015555-2856","article-title":"Validation of the Itch Severity Item as a measurement tool for pruritus in patients with psoriasis: Results from a phase 3 tofacitinib program","volume":"98","author":"Luger","year":"2018","journal-title":"Acta Derm. Venereol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/09546634.2013.865009","article-title":"The 5-point Investigator\u2019s Global Assessment (IGA) scale: A modified tool for evaluating plaque psoriasis severity in clinical trials","volume":"26","author":"Langley","year":"2015","journal-title":"J. Dermatol. Treat."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/1744666X.2018.1468252","article-title":"Quality of life in psoriatic arthritis","volume":"14","author":"Gudu","year":"2018","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/archdermatol.2011.178","article-title":"The impact of pruritus on quality of life: The skin equivalent of pain","volume":"147","author":"Kini","year":"2011","journal-title":"Arch. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1046\/j.1365-2133.2000.03829.x","article-title":"The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis","volume":"143","author":"Yosipovitch","year":"2000","journal-title":"Br. J. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2340\/00015555-0371","article-title":"Affective and sensory dimensions of pruritus severity: Associations with psychological symptoms and quality of life in psoriasis patients","volume":"88","author":"Zachariae","year":"2008","journal-title":"Acta Derm. Venereol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1001\/archderm.1988.01670070040016","article-title":"Pruritus in psoriasis. A prospective study of some psychiatric and dermatologic correlates","volume":"124","author":"Gupta","year":"1988","journal-title":"Arch. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00403-019-01998-7","article-title":"Pruritus and sleep disturbances in patients with psoriasis","volume":"312","author":"Hawro","year":"2020","journal-title":"Arch. Dermatol. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/annrheumdis-2020-eular.1052","article-title":"Identifying mediators of pain reduction in patients with psoriatic arthritis treated with tofacitinib: Role of inflammation associated with peripheral arthritis, enthesitis and skin disease","volume":"79","author":"Taylor","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Taylor, P.C., Lee, Y.C., Fleischmann, R., Takeuchi, T., Perkins, E.L., Fautrel, B., Zhu, B., Quebe, A.K., Gaich, C.L., and Zhang, X. (2019). Achieving pain control in rheumatoid arthritis with baricitinib or adalimumab plus methotrexate: Results from the RA-BEAM trial. J. Clin. Med., 8.","DOI":"10.3390\/jcm8060831"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/18\/4081\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:59:45Z","timestamp":1760165985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/18\/4081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,9]]},"references-count":35,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["jcm10184081"],"URL":"https:\/\/doi.org\/10.3390\/jcm10184081","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,9]]}}}